Concurrent effects of EMG-triggered NMES and anodal tDCS on cortical and behavioural outcome measures: The role of ipsilateral versus contralateral anodal stimulation.

Brain ResJul 10, 2026 (epub)
Clinical ResearchPhysical Medicine & RehabilitationNeurology

Hamed Alanazi, Prue Morgan, Shapour Jaberzadeh

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of concurrent electromyography-triggered neuromuscular electrical stimulation (EMG-triggered NMES) and anodal transcranial direct current stimulation (a-tDCS) on corticospinal excitability (CSE) and motor performance in 20 healthy adults. The study found that EMG-triggered NMES combined with contralateral a-tDCS significantly increased CSE, while ipsilateral a-tDCS improved maximal voluntary contraction and choice reaction time without affecting CSE.

Key findings

  • CSE increased significantly after EMG-triggered NMES + contralateral a-tDCS (p < 0.001).
  • EMG-triggered NMES + ipsilateral a-tDCS improved maximal voluntary contraction (P = 0.021).
  • Choice reaction time task performance improved with EMG-triggered NMES + ipsilateral a-tDCS (P = 0.035).
  • Contralateral a-tDCS reduced short-interval intracortical inhibition (P = 0.029).

Why it matters

Understanding the differential effects of neuromodulatory interventions on motor performance and corticospinal excitability can inform rehabilitation strategies aimed at enhancing neuroplasticity and functional recovery in patients with motor impairments.

Source

PubMed · PMID 42431572

Published in Brain Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.